Folger Nolan Fleming Douglas Capital Management Inc. Sells 50 Shares of Eli Lilly and Company (NYSE:LLY)

Folger Nolan Fleming Douglas Capital Management Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,216 shares of the company’s stock after selling 50 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Eli Lilly and Company were worth $3,041,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lipe & Dalton bought a new position in Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $35,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.2 %

Shares of NYSE LLY traded up $8.64 during mid-day trading on Friday, hitting $733.51. The company’s stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The stock has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a one year low of $380.77 and a one year high of $800.78. The company’s fifty day simple moving average is $761.79 and its 200-day simple moving average is $666.06.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.09 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Truist Financial reiterated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.